Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:STML Stemline Therapeutics (STML) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Stemline Therapeutics Stock (NASDAQ:STML) 30 days 90 days 365 days Advanced Chart Remove Ads Get Stemline Therapeutics alerts:Sign Up Key Stats Today's Range$11.83▼$11.8350-Day Range$11.83▼$11.8352-Week Range$3.21▼$18.22Volume1,084 shsAverage Volume1.52 million shsMarket Capitalization$621.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewStemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.Read More… Remove Ads Receive STML Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stemline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STML Stock News HeadlinesTrade These 7 Stocks Under $10 for Huge ProfitsApril 10, 2022 | thestreet.comBreakeven On The Horizon For Stemline Therapeutics Inc (NASDAQ:STML)October 26, 2021 | finance.yahoo.comSee More Headlines STML Stock Analysis - Frequently Asked Questions How were Stemline Therapeutics' earnings last quarter? Stemline Therapeutics Inc (NASDAQ:STML) released its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.08. The biopharmaceutical company had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million. Stemline Therapeutics had a negative trailing twelve-month return on equity of 48.14% and a negative net margin of 150.30%. What other stocks do shareholders of Stemline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Stemline Therapeutics investors own include TG Therapeutics (TGTX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), Sorrento Therapeutics (SRNE) and ZIOPHARM Oncology (ZIOP). Company Calendar Last Earnings11/07/2019Today3/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:STML CIK1264587 Webwww.stemline.com Phone646-502-2311FaxN/AEmployees92Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,820,000.00 Net Margins-150.30% Pretax MarginN/A Return on Equity-48.14% Return on Assets-41.35% Debt Debt-to-Equity RatioN/A Current Ratio7.43 Quick Ratio7.37 Sales & Book Value Annual Sales$43.22 million Price / Sales14.37 Cash FlowN/A Price / Cash FlowN/A Book Value$3.26 per share Price / Book3.63Miscellaneous Outstanding Shares52,511,000Free FloatN/AMarket Cap$621.21 million OptionableOptionable Beta1.78 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:STML) was last updated on 3/18/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredIs this the End of the AI Boom?If you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… ...Brownstone Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredMusk’s real agenda in D.C. Companies connected to Elon’s new map of America are making major climbs in price. And on May 30, the next wav...Porter & Company | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTitanic SyndromeStocks are experiencing a pattern known as the "Titanic Syndrome." I'm talking about the dramatic jump in t...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stemline Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stemline Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.